Literature DB >> 17379095

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Malcolm A S Moore1, David C Dorn, Jan Jacob Schuringa, Ki Young Chung, Giovanni Morrone.   

Abstract

OBJECTIVE: To model human leukemogenesis by transduction of human hematopoietic stem cells (HSC) with genes associated with leukemia and expressed in leukemic stem cells.
METHODS: Constitutive activation of Flt3 (Flt3-ITD) has been reported in 25 to 30% of patients with acute myeloid leukemia (AML). Retroviral vectors expressing constitutively activated Flt3 and STAT5A were used to transduce human cord blood CD34(+) cells and HSC cell self-renewal and differentiation were evaluated.
RESULTS: We have demonstrated that retroviral transduction of Flt3 mutations into CD34(+) cells enhanced HSC self-renewal as measured in vitro in competitive stromal coculture and limiting-dilution week-2 cobblestone (CAFC) assays. Enhanced erythropoiesis and decreased myelopoiesis were noted together with strong activation of STAT5A. Consequently, transduction studies were undertaken with a constitutively active mutant of STAT5A (STAT5A[1( *)6]) and here also a marked, selective expansion of transduced CD34(+) cells was noted, with a massive increase in self-renewing CAFC detectable at both 2 and 5 weeks of stromal coculture. Differentiation was biased to erythropoiesis, including erythropoietin independence, with myeloid maturation inhibition. The observed phenotypic changes correlated with differential gene expression, with a number of genes differentially regulated by both the Flt3 and STAT5A mutants. These included upregulation of genes involved in erythropoiesis and downregulation of genes involved in myelopoiesis. The phenotype of week-2 self-renewing CAFC also characterized primary Flt3-ITD(+) AML bone marrow samples. Isolation of leukemic stem cells (LSC) with a CD34(+), CD38(-), HLA-DR(-) phenotype was undertaken with Flt3-ITD(+) AML samples resulting in co-purification of early CAFC. Gene expression of LSC relative to the bulk leukemic population revealed upregulation of homeobox genes (HOXA9, HOXA5) implicated in leukemogenesis, and hepatic leukemia factor (HLF) involved in stem cell proliferation.
CONCLUSION: Myeloid leukemogenesis is a multi-stage process that can involve constitutively activated receptors and downstream pathways involving STAT5, HOX genes, and HLF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17379095     DOI: 10.1016/j.exphem.2007.01.018

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  21 in total

1.  High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.

Authors:  Benet Pera; M Nieves Calvo-Vidal; Srikanth Ambati; Michel Jordi; Alissa Kahn; J Fernando Díaz; Weishuo Fang; Karl-Heinz Altmann; Leandro Cerchietti; Malcolm A S Moore
Journal:  Cancer Lett       Date:  2015-08-12       Impact factor: 8.679

2.  STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Authors:  Winnie F Tam; Patricia S Hähnel; Andrea Schüler; Benjamin H Lee; Rachel Okabe; Nan Zhu; Saskia V Pante; Glen Raffel; Thomas Mercher; Gerlinde Wernig; Ernesto Bockamp; Daniel Sasca; Andreas Kreft; Gertraud W Robinson; Lothar Hennighausen; D Gary Gilliland; Thomas Kindler
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

3.  Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Authors:  Kshama Gupta; Inna Kuznetsova; Olga Klimenkova; Maksim Klimiankou; Johann Meyer; Malcolm A S Moore; Cornelia Zeidler; Karl Welte; Julia Skokowa
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

4.  Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.

Authors:  Anupama Narla; Shilpee Dutt; J Randall McAuley; Fatima Al-Shahrour; Slater Hurst; Marie McConkey; Donna Neuberg; Benjamin L Ebert
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

5.  Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse.

Authors:  Sangeetha V M; V M Sangeetha; Vaijayanti P Kale; Lalita S Limaye
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

6.  The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.

Authors:  C Nishioka; T Ikezoe; A Takeuchi; A Nobumoto; M Tsuda; A Yokoyama
Journal:  Leukemia       Date:  2015-08-11       Impact factor: 11.528

7.  Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels.

Authors:  Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

8.  Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.

Authors:  Kimberly A Hartwell; Peter G Miller; Siddhartha Mukherjee; Alissa R Kahn; Alison L Stewart; David J Logan; Joseph M Negri; Mildred Duvet; Marcus Järås; Rishi Puram; Vlado Dancik; Fatima Al-Shahrour; Thomas Kindler; Zuzana Tothova; Shrikanta Chattopadhyay; Thomas Hasaka; Rajiv Narayan; Mingji Dai; Christina Huang; Sebastian Shterental; Lisa P Chu; J Erika Haydu; Jae Hung Shieh; David P Steensma; Benito Munoz; Joshua A Bittker; Alykhan F Shamji; Paul A Clemons; Nicola J Tolliday; Anne E Carpenter; D Gary Gilliland; Andrew M Stern; Malcolm A S Moore; David T Scadden; Stuart L Schreiber; Benjamin L Ebert; Todd R Golub
Journal:  Nat Chem Biol       Date:  2013-10-27       Impact factor: 15.040

9.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

10.  Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.

Authors:  William F Richter; Rohan N Shah; Alexander J Ruthenburg
Journal:  Elife       Date:  2021-07-15       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.